Scott Rottinghaus
Directeur Technique/Scientifique/R&D chez ENANTA PHARMACEUTICALS, INC.
Fortune : 353 022 $ au 30/04/2024
Postes actifs de Scott Rottinghaus
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 08/08/2022 | - |
Historique de carrière de Scott Rottinghaus
Anciens postes connus de Scott Rottinghaus
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Formation de Scott Rottinghaus
| Mayo Medical School | Doctorate Degree |
| University of Cambridge | Graduate Degree |
| Kansas State University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| 2 | |
| Royaume-Uni | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Consumer Services | 4 |
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Bourse
- Insiders
- Scott Rottinghaus
- Expérience